Video Experimental Relacionado
Updated: May 5, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.9K
El cofactor de heparina II es un nuevo factor protector contra la aterosclerosis carotídea en personas mayores
Ken-ichi Aihara1, Hiroyuki Azuma, Nobuyuki Takamori
1Department of Medicine and Bioregulatory Sciences, University of Tokushima, Graduate School of Medicine, Kuramoto-cho Tokushima, Japan.
Circulation
|May 19, 2004
Resumen
La actividad del cofactor II de heparina (HCII) puede prevenir la aterosclerosis. Los niveles más altos de HCII se correlacionan con la reducción del grosor de la placa carotídea, lo que sugiere que es un factor antiaterogénico más fuerte que el colesterol HDL en los ancianos.
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- La bioquímica es la bioquímica.
- Gerontología Gerontología.
Sus antecedentes:
- La trombina es clave en la atherothrombosis.
- El cofactor de heparina II (HCII) inhibe la trombina en los sitios de lesión arterial.
- HCII puede regular la actividad de la trombina vascular.
Objetivo del estudio:
- Para investigar la actividad plasmática HCII como un factor preventivo contra la aterosclerosis.
- Para evaluar el papel de HCII en personas mayores con lesiones vasculares existentes.
Principales métodos:
- La ecografía midió el espesor máximo de la placa de la arteria carótida (MPT) en 306 individuos japoneses de edad avanzada.
- El análisis estadístico evaluó los factores de riesgo cardiovascular, incluida la actividad HCII plasmática, frente a la MPT.
- Los análisis de regresión identificaron predictores independientes de la MPT.
Principales resultados:
- La actividad plasmática HCII disminuyó con la edad.
- Las lipoproteínas (((a), HbA1c y la diabetes mellitus aumentaron la TMP.
- El colesterol de lipoproteínas de alta densidad (HDL) y la actividad HCII se correlacionaron negativamente con la TMP.
- La actividad de HCII y el colesterol HDL suprimieron independientemente la MPT, siendo HCII un factor más fuerte.
Conclusiones:
- HCII es un factor antiaterogénico nuevo e independiente.
- HCII es un predictor más fuerte que el colesterol HDL contra la aterosclerosis carotídea en los ancianos.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482